Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.65) by 1.54 percent. This is a 1.69 percent increase over losses of $(0.65) per share from the same period last year. The company reported quarterly sales of $10.483 million which beat the analyst consensus estimate of $7.230 million by 44.99 percent. This is a 51.19 percent decrease over sales of $21.475 million the same period last year.